Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Outset Medical, Inc.'s SEC filings document operating results, product and service revenue, gross margin, cash resources, and guidance for its dialysis technology business. Recent Form 8-K reports furnish earnings releases for the Tablo Hemodialysis System business and disclose material events such as FDA 510(k) clearance for the next-generation Tablo platform.
Proxy materials and current reports also cover governance and compensation matters, including board composition, director independence, committee appointments, executive compensation tables, pay-versus-performance disclosures, and equity awards. The filing record ties these disclosures to Outset’s capital structure, Nasdaq-listed common stock, and medical-device regulatory environment.
Brottem John L. reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. reported that its General Counsel, John L. Brottem, received a grant of 59,830 restricted stock units (RSUs) of common stock on June 26, 2026. Each RSU represents one share of common stock. Following this award, his direct holdings total 90,107 shares. The RSUs vest 33.33% on June 26, 2027, with the remaining 66.67% vesting in equal quarterly installments over the next two years, subject to his continuous service.
Gaeta Renee reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc.’s Chief Financial Officer, Renee Gaeta, reported a grant of 71,630 shares of common stock in the form of restricted stock units. The award was granted at no cash cost and raises her direct holdings to 185,383 shares after the transaction.
Each RSU represents the right to receive one share of common stock if it vests. The units vest 33.33% on June 26, 2027, with the remaining 66.67% vesting in equal quarterly installments over the following two years, as long as she remains in continuous service.
Trigg Leslie reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. Chair and CEO Leslie Trigg received a grant of 99,160 restricted stock units (RSUs) of common stock as equity compensation. Each RSU represents the right to receive one share of common stock if vesting conditions are met.
The RSUs vest 33.33% on June 26, 2027, with the remaining 66.67% vesting in equal quarterly installments over the following two years on February 15, May 15, August 15, and November 15, subject to continued service. After this grant, Trigg holds 198,034 shares directly, plus indirect holdings of 584 shares via the Trigg Family Trust and 41,666 shares via the Trigg 2002 Rev Trust.
Outset Medical, Inc. entered into a Refresh Amendment to its Purchasing Agreement with HCA Management Services, under which HCA will refresh its fleet of Tablo Hemodialysis Systems. HCA plans to purchase new Tablo systems from 2026 through the end of 2028 for an aggregate contract value of approximately $40 million, net of rebates and allowances.
The agreement is described as a committed capital purchase and includes a console and consumables purchase framework that can support potential future growth beyond HCA hospitals already using Tablo. Outset Medical is reiterating its previously issued 2026 guidance and expects to provide more detail on the 2026 financial impact of this amendment later in the year once it better understands the timing and ramp of implementation.
HACKETT PATRICK T reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. director Patrick T. Hackett received a grant of 10,667 shares of common stock as a stock award at a stated price of $0.00 per share. These RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders.
Following this grant, Hackett holds 105,839 shares of Outset Medical common stock directly. He also has indirect ownership of 41,666 shares through the Hackett Family Fund and 83,333 shares through the GST Trust as of the transaction date.
OBOYLE KEVIN C reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. director Kevin C. O’Boyle received an equity award in the form of restricted stock units covering 10,667 shares of common stock. The award was recorded at a price of $0.00 per share as a compensation grant, not a market purchase.
Following this award, O’Boyle directly holds 34,785 shares of Outset Medical common stock. According to the disclosure, 100% of the shares underlying these RSUs will vest upon the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders.
Prange Karen reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical director Karen Prange received a new equity award in the form of restricted stock units (RSUs). The grant covers 10,667 shares of common stock at no cash cost, increasing her direct holdings to 29,334 shares after the transaction.
According to the terms, 100% of the shares underlying these RSUs will vest on the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders. This award is compensation-related, not an open-market stock purchase.
LANG BRENT D. reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. director Brent D. Lang received a grant of 10,667 shares of Common Stock as a stock award at a stated price of $0.0000 per share. These shares represent the underlying restricted stock units.
According to the terms, 100% of the shares underlying these RSUs will vest upon the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders. Following this award, Lang holds 28,518 shares directly and 16,666 shares indirectly through the Lang Family Trust.
GROSSMAN D KEITH reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. director D. Keith Grossman reported an equity award and updated holdings. He received a grant of 10,667 shares of Common Stock at $0.00 per share, described in the footnote as shares underlying RSUs that will vest 100% on the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders. Following the grant, he holds 24,585 shares directly and 12,845 shares indirectly through the Grossman Fam Trust.
Drexler Karen reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. director Karen Drexler reported an equity award of common stock as compensation. She received 10,667 shares at a price of $0.00 per share, reflecting a grant rather than an open-market purchase or sale.
According to the filing, 100% of the shares underlying these RSUs will vest upon the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders. Following the grant, Drexler directly holds 21,317 shares of common stock and indirectly holds 2,083 shares through the Drexler Family Trust.